203 related articles for article (PubMed ID: 22042950)
1. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: findings from the Breast Cancer Family Registry.
Kurian AW; Gong GD; John EM; Johnston DA; Felberg A; West DW; Miron A; Andrulis IL; Hopper JL; Knight JA; Ozcelik H; Dite GS; Apicella C; Southey MC; Whittemore AS
J Clin Oncol; 2011 Dec; 29(34):4505-9. PubMed ID: 22042950
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
3. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
Smith A; Moran A; Boyd MC; Bulman M; Shenton A; Smith L; Iddenden R; Woodward ER; Lalloo F; Maher ER; Evans DG
J Med Genet; 2007 Jan; 44(1):10-15. PubMed ID: 17079251
[TBL] [Abstract][Full Text] [Related]
4. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
[TBL] [Abstract][Full Text] [Related]
5. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
6. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929
[TBL] [Abstract][Full Text] [Related]
7. Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.
Evans DG; Ingham SL; Buchan I; Woodward ER; Byers H; Howell A; Maher ER; Newman WG; Lalloo F
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2269-76. PubMed ID: 24285840
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
Peto J; Collins N; Barfoot R; Seal S; Warren W; Rahman N; Easton DF; Evans C; Deacon J; Stratton MR
J Natl Cancer Inst; 1999 Jun; 91(11):943-9. PubMed ID: 10359546
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
[TBL] [Abstract][Full Text] [Related]
11. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
Milne RL; Knight JA; John EM; Dite GS; Balbuena R; Ziogas A; Andrulis IL; West DW; Li FP; Southey MC; Giles GG; McCredie MR; Hopper JL; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):350-6. PubMed ID: 15734957
[TBL] [Abstract][Full Text] [Related]
13. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
14. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.
Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER
BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ.
Claus EB; Petruzella S; Matloff E; Carter D
JAMA; 2005 Feb; 293(8):964-9. PubMed ID: 15728167
[TBL] [Abstract][Full Text] [Related]
16. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
Claus EB; Schildkraut J; Iversen ES; Berry D; Parmigiani G
J Natl Cancer Inst; 1998 Dec; 90(23):1824-9. PubMed ID: 9839523
[TBL] [Abstract][Full Text] [Related]
17. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
18. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identification of four novel mutations and high-frequency occurrence of 185delAG mutation.
Vaidyanathan K; Lakhotia S; Ravishankar HM; Tabassum U; Mukherjee G; Somasundaram K
J Biosci; 2009 Sep; 34(3):415-22. PubMed ID: 19805903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
